| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 246.74% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/14/2022 | 246.74% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
What is the target price for BriaCell Therapeutics (BCTX)?
The latest price target for BriaCell Therapeutics (NASDAQ: BCTX) was reported by HC Wainwright & Co. on February 24, 2023. The analyst firm set a price target for $25.00 expecting BCTX to rise to within 12 months (a possible 246.74% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?
The latest analyst rating for BriaCell Therapeutics (NASDAQ: BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price BriaCell Therapeutics (BCTX) is trading at is $7.21, which is within the analyst's predicted range.